Moderna (MRNA) is back in focus after fresh clinical data showed its mRNA 1010 flu shot outperformed standard vaccines in adults over 50. Early hantavirus work has also gained attention following a cruise ship outbreak.

Those flu and hantavirus updates arrive as Moderna’s share price pulls back in the very short term, with a 1-day share price return of 1.98% and a 7-day share price return of 9.77% on the downside. A 90-day share price return of 16.13% and year to date share price return of 58.91% point to strong recent momentum, while a 1-year total shareholder return of 97.26% contrasts with steep total shareholder return declines over three and five years. This suggests sentiment has only recently improved.

If the renewed interest in mRNA vaccines has your attention, it could be a good moment to see what else is moving in healthcare and review 32 healthcare AI stocks

With Moderna still reporting losses and the stock trading below the average analyst price target, investors are now weighing the recent mRNA wins and pipeline buzz. Is there real upside left, or are markets already pricing in future growth?

Most Popular Narrative: 72% Undervalued

According to the most followed narrative, Moderna’s fair value of $175 sits well above the last close of $49.04, which puts the recent pullback in a different light.

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance. Less well-known is how Moderna reinvested the windfall in the wake of its success. The company has spent years plowing its profits into new innovations while maintaining a relatively pristine balance sheet for a company as large as it is. In biotech it is not uncommon for companies to keep low levels of debt. Moderna is unique among its peers for its particularly low valuation relative to its assets. Currently, the company is trading below its book value, with the potential for significant growth depending on how any one of its numerous drug and treatment investments turn out. Even without any additional investment in medical innovation, the company has a lot of products in its pipeline ready to go.

This narrative from woodworthfund focuses on how Moderna used its COVID windfall, its asset base, and a maturing pipeline to underpin that $175 figure. Want to see which revenue ramp, margin path, and valuation multiple assumptions are doing the heavy lifting behind that gap to today’s $49.04 share price.

Result: Fair Value of $175 (UNDERVALUED)

However, recent share price weakness and ongoing net losses of US$3,194m mean any setback in the pipeline, or slower revenue growth of 23.82%, could quickly challenge that optimism.

Another Angle On Valuation

The popular $175 fair value view leans heavily on long term potential, but the current P/S ratio of 8.7x paints a tougher picture. It is lower than the US Biotechs industry average of 10.6x, yet far above the fair ratio estimate of 1.6x. This points to meaningful valuation risk if sentiment cools.

For a closer look at how this pricing gap aligns with business fundamentals, review the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.. It includes how the current P/S compares with peers and that 1.6x fair ratio baseline.

Next Steps

If this mix of optimism and caution has you thinking, now is the time to check the data yourself and decide where you stand. To see what is driving that optimism before sentiment shifts again, review the 1 key reward.

Looking for more investment ideas?

If Moderna has you thinking differently about your portfolio, do not stop here. The widest opportunities often sit just beyond the first stock that catches your eye.

• Target steady compounding potential with 12 dividend fortresses to help you focus on income while still being selective about quality.
• Hunt for pricing gaps using 50 high quality undervalued stocks where solid fundamentals may not yet be fully reflected in current share prices.
• Prioritise resilience first with 66 resilient stocks with low risk scores so you are not the one wishing you had checked the downside before the next bout of volatility hits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.